Navigation Links
InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
Date:12/10/2008

sign of the Phase 2 program. The study objectives are to assess the safety, pharmacokinetic and viral kinetic effects of ITMN-191 administered for 14 days in combination with Pegasys and Copegus compared to the effects of Pegasys and Copegus alone. The protocol includes both twice-daily and three-times-daily ITMN-191 regimens starting with a total daily dose of 300mg.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating new targets in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Spherix Reports Second Quarter Earnings
11. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014  Mark Riccio, director of Cornell University,s ... using the online crowd-funding platform Kickstarter to bring ... researchers and would-be superheros everywhere: "for FREE." Riccio,s ... do if you had Superman,s X-ray vision?" The ... everywhere, from elementary through high school students, academic ...
(Date:8/22/2014)... , August 22, 2014 ... TVs Today Lincor announced general availability of ... solution that delivers a range of education, entertainment and ...      (Logo: http://photos.prnewswire.com/prnh/20140822/702945) , " ... point of care patient engagement to bedside smart devices, ...
(Date:8/22/2014)... COLORADO SPRINGS, Colo. , Aug. 22, 2014 ... Company specializing in cannabis formulation-based drug development and ... of UFCM iCare,s third international medical cannabis conference ... Strasbourg, France , on October ... experts with other stakeholders, such as researchers, health ...
Breaking Medicine Technology:Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2Lincor Unveils Next Generation TV-based Patient Engagement Solution 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3
(Date:8/22/2014)... European Society for Medical Oncology (ESMO), the leading ... the names of three outstanding individuals receiving the ... presented to Carsten Bokemeyer, Heikki Joensuu and Peter ... Congress, 26-30 September, Madrid, Spain. , Carsten Bokemeyer ... to accelerate the transition of cancer discovery into ...
(Date:8/22/2014)... 22, 2014 Braverman Eye Center is ... Lauderdale at the most affordable fee. They are on ... their advanced Lasik treatments. LASIK is a highly successful ... Eye Center has been delivering successful LASIK solutions to ... glasses-free and contact lenses-free life with the help of ...
(Date:8/22/2014)... The report "Higher Education Market [Software Solutions, Content ... Student & Curriculum, Performance Management] - Worldwide Market ... global Higher Ed market into various sub-segments with ... The report also identifies the factors driving this ... with the adoption trends. , Browse more ...
(Date:8/22/2014)... Each year approx. 265,000 Danes are acutely admitted to ... from Aarhus University and Aarhus University Hospital now shows ... fourth patient are sent home again without receiving ... the acute hospitalisation., "Naturally, there is no need for ... that there is a serious illness. So some patients ...
(Date:8/22/2014)... a wide range of epigenetic changesalterations in DNA across ... children with Crohn,s disease (CD), reports Inflammatory Bowel ... Colitis Foundation of America (CCFA). The journal is ... of Wolters Kluwer Health . , The ... regions of the genome in children with CD, according to ...
Breaking Medicine News(10 mins):Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:Braverman Eye Center Now Offers Lasik Treatment in Fort Lauderdale at the Most Affordable Fee 2Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Many patients are discharged without a diagnosis 2Health News:Study shows epigenetic changes in children with Crohn's disease 2
... GIFT IDEA FOR THE DOG, CAT, ANIMAL LOVER ON YOUR LIST ... Betty White, Emmy-award winner and TV legend, is also one of ... more than 40 years, she has been a tremendous supporter of ... of the organization,s board of trustees and is a current trustee. ...
... TV Movie Portrayal of Tourette Syndrome , ... million people watched last Sunday night,s Hallmark Hall of Fame ... on the true story of a young man,s struggles with ... winning teacher. The national Tourette Syndrome Association, Inc. (TSA) ...
... could be part of mental exercise routine for older ... Older people who want to stay sharp should reconsider ... children and pick up a joystick themselves, a new ... playing video games has many positive benefits, ranging from ...
... in the clinic and the laboratory continue to work ... drugs. With tamoxifen,s discovery 30 years behind us, and ... studying zoledronic acid, aromatase inhibitors and monoclonal antibodies, among ... the CTRC-AACR San Antonio Breast Cancer Symposium. , ...
... of the largest studies in hormone receptor positive women ... , PHILADELPHIA, Dec. 11 New results ... (lapatinib) plus Femara(R) (letrozole) versus letrozole alone as a ... breast cancer. In the study, women diagnosed with post-menopausal, ...
... Sister Carol Keehan, DC, president and chief executive officer ... issued the following statement: , , ... nomination today of former Senate Majority Leader Tom Daschle to ... person to oversee a new White House Office of Health ...
Cached Medicine News:Health News:Betty White's Video States Support for Funding Humane Research to Help Pets and Wild Animals - Actress is 40-Year Champion of Morris Animal Foundation 2Health News:Hallmark Hall of Fame Collaboration with Patient Organization Equals Extraordinary Success 2Health News:Playing Video Games May Boost Older Brains 2Health News:Playing Video Games May Boost Older Brains 3Health News:Cancer drugs in the pipeline 2Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 2Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 3Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 4Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 5Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 6Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 7Health News:Catholic Health Association Statement on the Naming of Tom Daschle and Jeanne Lambrew to Health Leadership Positions in President-Elect Obama's Administration 2
... Renu Multiplus preservative free lubricating ... moisturize your eyes while you're ... gentle preservative free formula is ... be sensitive to preservatives and ...
... Multiplus No Rub formula is the most ... All steps in one bottle without the ... soft contact lenses and removes protein build-up ... solution that contains Hydranate, a special ingredient ...
... Sensitive Eyes saline solution ... saline solution for people ... solution for rinsing soft ... or chemical disinfection. May ...
... enzymatic cleaner is a fast-acting ... stubborn deposits in as little ... enzymatic cleaner contains an enzyme ... film on soft contact lenses ...
Medicine Products: